Paragraph IV notice management that sets the 45-day clock and shows what is new, the same day
The 45-day clock set and a cited response pack ready the same day.
See one case, screen by screen ↓It is how a brand's patent team handles a Paragraph IV notice letter from the day it is received: checking the notice, setting the 45-day suit window and the 30-month stay, answering the detailed statement and deciding whether to sue. Paragraph IV Notice Management adds six agents that read the notice, set the clocks, map each argument to the claims it attacks and compare it with every earlier challenge, for counsel to review and the Chief Patent Counsel to sign.
How to choose AI solutions for life sciences →
Updated
A Paragraph IV notice letter starts a 45-day clock from the day it is received: sue in time and FDA cannot approve the generic for up to 30 months; miss it and the stay is gone. Before anyone can rely on that date, someone has to confirm the courier receipt, check that the notice is valid under 21 CFR 314.95 and work out what happens when day 45 falls on a weekend.
Then the detailed statement has to be read claim by claim. Each filer sends its own, and most of the arguments repeat earlier challenges to the same patents. Today counsel and outside counsel re-read every statement by hand, rebuild the claim chart and search old briefs, expert reports and file histories from memory — about 12 days to a first-response pack, paying twice for arguments already answered.
Estimated split for one Paragraph IV notice on a product with earlier challengers, by hand and with the solution, in days.
Six specialist agents read the notice, set the clock, map each argument to the claims and compare it with every earlier challenge; counsel reviews and the Chief Patent Counsel decides.
Northwind Bio sells Corventa, vandorixant tablets 10 mg for heart failure with reduced ejection fraction. Halvard and Ivel are already in suit in Delaware, and Brightwell Pharma's notice arrived two days ago. On Wednesday, October 7, 2026, a notice from Juniper Generics is signed for at 08:41. Here is what happens next, screen by screen, in the working solution.
Juniper's notice of Paragraph IV certification arrives by courier: ANDA 220455, a Paragraph IV certification to the ’772 and ’418 and a Paragraph III certification to the ’207. Lena confirms the courier receipt at 08:42. The statutory clock shows “clock not set” until the letter is read and confirmed valid.
“The clock runs from the courier receipt, not the date on the letter. It is set once the letter is confirmed valid.”
Dana Okafor clicks Read the notice. The Notice Reader checks the letter was sent after FDA's acknowledgment letter (received Sep 30, notice dated Oct 5) and within 20 days of it, the ANDA number and product, every listed patent, a detailed statement claim by claim on pages 9–27, the offer of confidential access and the receipt proof. No US agent is needed: Juniper is a Delaware company.
The Notice Reader never starts a clock without a receipt proof, and flags — never fixes — a defective notice.
The Clock Keeper draws the 45-day window from the receipt. Day 45 is Saturday, Nov 21, so the target is the business day before: the complaint on file by Friday, Nov 20. If suit is filed in time, FDA cannot approve Juniper's ANDA before Apr 7, 2029, unless a court rules first. The litigation hold is due Oct 9 and the request for ANDA access Oct 16, with alerts at 30, 14, 7, 3 and 1 days to Dana Okafor and Omar Haddad.
“Day 45 is Sat, Nov 21 — a weekend, so the complaint goes on file Fri, Nov 20.”
The Contention Mapper splits the detailed statement into 9 arguments against 8 claims of the ’772 and ’418, each with its ground and page. The Prior Positions Finder compares each one with Halvard, Ivel and Brightwell: 5 answered before, 2 answered by our own record, 2 new. Obviousness over the 2012 dose-ranging study is answered by the Voss reply report; double patenting over the ’546 by the terminal disclaimer filed Jul 18, 2017.
The Prior Positions Finder never states a legal conclusion — it gives counsel the material and a labelled assessment.
J7 says Juniper's tablet releases 76% at 12 hours, below claim 9's 80%; Brightwell argued 70% on Oct 5 and that is still open. It is fact-dependent, so its next action, “Ask for dissolution data”, is routed to the formulation expert. J9 says the 10 mg strength is not described — never argued against Northwind; Example 3 tablets are 10 mg, and counsel is to confirm the wording.
“New and fact-dependent — ask for the ANDA dissolution data under confidential access.”
Dana opens matter M-2615. The claim-by-ground chart shows each claim of the ’772 and ’418 across not infringed, no inducement, anticipated, obvious, indefinite or not described, and double patenting, with J7 and J9 in red. The letter sits beside it, highlighted where the reader took each fact.
The litigation hold goes to the same 31 Corventa custodians as the Brightwell hold, plus Juniper-specific correspondence owners, adding dissolution work on polyethylene-oxide matrices; acknowledgements by Oct 14, tracked by Lena Ortiz. The briefing to Whitcombe & Rowe says what is new, what is already answered and what is asked: consider joining Juniper to the Brightwell complaint in Delaware, with the first pass budgeted at 25 hours.
Nothing leaves without a named person's sign-off: Dana Okafor for the hold, Sam Patel for the briefing.
The suit decision shows 45 days left and the four options: sue on ’772 and ’418 in Delaware, related to the Brightwell case (recommended — Juniper is a Delaware company); ask for Juniper's ANDA first, then sue; sue on ’772 only; or do not sue and keep watching. The note to outside counsel names the claims to assert and asks for the ANDA to test the 76% release figure.
“Do not sue — keep watching: the stay is lost after Sat, Nov 21; Juniper may then seek a declaratory judgment.”
Omar signs: sue on ’772 and ’418 in Delaware, related to the Brightwell case. Whitcombe & Rowe are instructed, the stay is protected to Apr 7, 2029, and the matter moves to the suit-decision stage. The signature is recorded in the audit trail.
“Signing as Omar Haddad, Chief Patent Counsel · recorded in the audit trail.”
The same notice, seen by the five people who carry it — what the first two weeks looked like, and what they look like now.
Six specialist agents read the notice, set the clock, map each argument to the claims and compare it with every earlier challenge; counsel reviews and the Chief Patent Counsel decides.
Reads each notice letter, biosimilar notice and detailed statement; extracts the application, product, strength, each listed patent with its expiry, the certification per patent and the courier receipt, and runs the 21 CFR 314.95 checks.
Computes the 45-day suit window, the 30-month stay, the patent-dance steps and IPR responses, applies weekend and court-holiday rules, writes each date to the docket and sets the alerts.
Splits the detailed statement into contentions and links each to the claims it attacks and its ground — non-infringement, anticipation, obviousness, §112, double patenting — with the references relied on.
Matches each contention to what was argued before — orders, expert reports, IPR papers, file histories — and labels it answered before, answered by the record, or new, saying what would test a new one and who should look.
Drafts the litigation-hold notice, the outside-counsel briefing and the suit-decision memo inputs from the matter, the chart and the clocks — every statement cited.
Runs the biosimilar patent dance under 42 USC 262(l) for each applicant — application, our list, their statement, our response, negotiation and suit — with the clock for each step, and routes each list and response to counsel.
Signs the suit decision. The agents propose; a named person decides.
Ask in plain words about a suit deadline, what is new in a detailed statement or what was argued before — or tell it what to change. Answers point to the page they came from.
When must we sue Juniper?
By Friday, Nov 20, 2026. Juniper's notice was delivered on Oct 7 at 08:41, so day 45 is Saturday, Nov 21. Whether a weekend extends the statutory window is not settled, so the Clock Keeper set the target to the business day before. The notice passed 8 of 8 checks, and the stay if we sue in time runs to Apr 7, 2029.
What is new in Brightwell's arguments?
Four of Brightwell's 11 contentions are new: the osmotic-pump tablet with no hydrophilic matrix, HPMC at only 12%, not more than 70% release at 12 hours, and the Kessler 2013 congress abstract. The abstract is the one to watch: it was never before the examiner, and it says nothing about eGFR or beta-blockers — so claims 7 and 11 stand clear of it.
How serious is the Kessler abstract?
It is the one genuinely new attack. The abstract describes 10 mg once daily in 48 patients with HFrEF, published a year before the Nov 4, 2014 priority date, and it was never cited to the examiner or raised by Halvard or Ivel. Exposure: ’772 claims 1 and 3. Next step: Whitcombe & Rowe's validity read before the complaint is final.
Alert me 10 days before every suit deadline
Done — a new rule: alert 10 days before every 45-day suit deadline, to you and Omar Haddad. Brightwell Pharma's deadline is Nov 19, so the alert goes on Nov 9; Juniper Generics' target is Nov 20, so the alert goes on Nov 10.
13 screens from the working solution, on its sample data. Pick one to see it large.
How clocks are counted, who approves what and who may see restricted material are settings, and every change is recorded in the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Alert before a deadline | 30, 14, 7, 3 and 1 days | 60d · 30d · 14d · 10d · 7d · 3d · 1d |
| Escalate an unacknowledged alert after 24 hours | Omar Haddad | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| What starts a 45-day suit window | Courier receipt, confirmed by a paralegal | Courier receipt, confirmed by a paralegal · Date on the letter · Scan time |
| When day 45 falls on a weekend or court holiday | Warn and set the target to the business day before | Warn and set the target to the business day before · Roll to the next business day |
| Suit decisions approved by | Omar Haddad | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| Litigation holds approved by | Dana Okafor | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| Outside-counsel briefings approved by | Sam Patel | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| Confidential-access ANDA material visible to | Outside counsel + Dana Okafor | Outside counsel + Dana Okafor · Outside counsel only |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample data · “target” = the design goal, measured in the live solution · “estimated” = our estimate · “typical” = set by statute (21 USC 355(j)(5)(B)(iii) — the 45-day suit window and the 30-month stay; 21 CFR 314.95 — notice requirements; 42 USC 262(l) — the biosimilar patent dance). People, companies, products, patents and matters named on this page are fictional — characters and sample data in the working solution.
It is how a brand's patent team handles a Paragraph IV notice letter from the day it is received: checking the notice, setting the 45-day suit window and the 30-month stay, answering the detailed statement and deciding whether to sue. Paragraph IV Notice Management adds six agents that read the notice, set the clocks, map each argument to the claims it attacks and compare it with every earlier challenge, for counsel to review and the Chief Patent Counsel to sign.
From the courier receipt, confirmed by a paralegal — not the date on the letter. By default, when day 45 falls on a weekend or court holiday it warns and sets the target to the business day before (you can choose to roll to the next business day instead); in the sample case day 45 is Saturday, Nov 21, so the complaint goes on file Friday, Nov 20. The dates go to the docket with alerts at 30, 14, 7, 3 and 1 days.
Yes. The Notice Reader runs the 21 CFR 314.95 checks — sent after FDA's acknowledgment letter and within 20 days of it, the application number, every listed patent, a detailed statement claim by claim, an offer of confidential access where non-infringement is alleged, and a US agent where needed — each cited to its page. A defective notice is flagged for counsel, never fixed.
The Prior Positions Finder searches the litigation record and file histories for the same argument, reference or fact, and labels each contention answered before (citing the order, brief or report), answered by the record (citing the file history or specification) or new. New ones sort to the top with what would test them and who should look.
Yes. The Dance Tracker runs the 42 USC 262(l) steps for each biosimilar applicant — the application, our patent list, their statement, our response, negotiation and suit — each with its clock, and routes every list and response to counsel for approval.
ANDA content received under an offer of confidential access, and application material under 42 USC 262(l)(1), is visible to outside counsel and one named in-house lawyer only — or to outside counsel only, if you choose. Every draft is stamped privileged on every page.
Yes. The agents never state a legal conclusion and never send anything outside the company. Counsel reviews each assessment, a named person signs off every hold and briefing, and the suit decision needs the Chief Patent Counsel's signature, recorded in the audit trail.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your patent estate, file histories, past litigation record and a sample of past notice letters — and it goes live once every quality gate has passed. We will walk you through it on your own notices first.
A cited generic entry date per market within hours of any change.
1-min demoContract Review & RedliningCounterparty contracts redlined and back in under two days.
1-min demoAlliance Milestone & Obligation TrackingEach milestone caught within a day of its trigger, amended amount and clock worked out.
1-min demoWe'll run Paragraph IV Notice Management on a sample of your own past notice letters and detailed statements.